{"id":"chlorpromazine-pill","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Drowsiness"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-15%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Parkinsonian symptoms"}]},"_chembl":{"chemblId":"CHEMBL71","moleculeType":"Small molecule","molecularWeight":"318.87"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to a decrease in the activity of the dopaminergic system, which is involved in the regulation of movement and other functions. Chlorpromazine's mechanism of action is complex and multifaceted, involving the blockade of multiple dopamine receptor subtypes. This results in a range of therapeutic effects, including the reduction of psychotic symptoms and the management of movement disorders.","oneSentence":"Chlorpromazine acts as a dopamine antagonist, blocking dopamine receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:36.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Acute psychosis"}]},"trialDetails":[{"nctId":"NCT04224441","phase":"PHASE2","title":"Repurposing Chlorpromazine in the Treatment of Glioblastoma","status":"UNKNOWN","sponsor":"Marco G Paggi, MD, PhD","startDate":"2019-12-15","conditions":"Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Temozolomide"],"phase":"phase_2","status":"active","brandName":"Chlorpromazine Pill","genericName":"Chlorpromazine Pill","companyName":"Marco G Paggi, MD, PhD","companyId":"marco-g-paggi-md-phd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chlorpromazine acts as a dopamine antagonist, blocking dopamine receptors in the brain. Used for Schizophrenia, Acute psychosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}